Nifty
Sensex
:
:
15746.45
52578.76
-78.00 (-0.49%)
-316.65 (-0.60%)

Pharmaceuticals & Drugs - Global

Rating :
64/99

BSE: 524742 | NSE: CAPLIPOINT

904.90
27-Jul-2021
  • Open
  • High
  • Low
  • Previous Close
  •  962.00
  •  1034.80
  •  886.35
  •  944.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  4255269
  •  40768.11
  •  1034.80
  •  381.15

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 7,153.16
  • 29.52
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 6,966.21
  • 0.16%
  • 6.03

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.03%
  • 1.62%
  • 21.69%
  • FII
  • DII
  • Others
  • 1.15%
  • 1.33%
  • 5.18%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 29.31
  • 16.94

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 32.37
  • 5.96

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 36.26
  • 14.09

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.85
  • 19.71
  • 17.19

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.92
  • 9.17
  • 4.64

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.86
  • 16.88
  • 11.20

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Net Sales
278.71
215.23
29.49%
274.39
228.21
20.24%
268.12
227.20
18.01%
240.08
192.55
24.68%
Expenses
193.02
161.42
19.58%
190.46
160.45
18.70%
180.69
156.09
15.76%
168.48
125.17
34.60%
EBITDA
85.69
53.81
59.25%
83.93
67.76
23.86%
87.43
71.11
22.95%
71.60
67.38
6.26%
EBIDTM
30.75%
25.00%
30.59%
29.69%
32.61%
31.30%
29.82%
34.99%
Other Income
9.46
19.63
-51.81%
5.82
10.34
-43.71%
1.76
6.89
-74.46%
6.49
4.47
45.19%
Interest
0.32
0.17
88.24%
0.28
0.06
366.67%
0.48
0.08
500.00%
0.51
0.01
5,000.00%
Depreciation
9.86
8.40
17.38%
9.27
8.42
10.10%
8.88
7.40
20.00%
8.96
7.39
21.24%
PBT
84.97
64.87
30.99%
80.20
69.62
15.20%
79.83
70.52
13.20%
68.62
64.45
6.47%
Tax
17.05
16.01
6.50%
14.06
10.73
31.03%
17.00
13.25
28.30%
14.07
14.39
-2.22%
PAT
67.92
48.86
39.01%
66.14
58.89
12.31%
62.83
57.27
9.71%
54.55
50.06
8.97%
PATM
24.37%
22.70%
24.10%
25.81%
23.43%
25.21%
22.72%
26.00%
EPS
8.77
6.46
35.76%
8.52
7.74
10.08%
7.52
7.58
-0.79%
7.21
6.64
8.58%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Jun 12
Jun 11
Net Sales
1,061.30
863.20
648.69
539.84
401.65
238.72
251.77
173.09
127.03
107.22
80.78
Net Sales Growth
22.95%
33.07%
20.16%
34.41%
68.25%
-5.18%
45.46%
36.26%
18.48%
32.73%
 
Cost Of Goods Sold
471.74
413.16
288.78
238.18
184.93
121.16
135.62
102.58
84.45
77.36
60.88
Gross Profit
589.56
450.04
359.91
301.66
216.72
117.56
116.15
70.50
42.58
29.85
19.89
GP Margin
55.55%
52.14%
55.48%
55.88%
53.96%
49.25%
46.13%
40.73%
33.52%
27.84%
24.62%
Total Expenditure
732.65
602.27
416.84
344.52
276.84
174.51
192.06
136.90
104.68
96.06
71.58
Power & Fuel Cost
-
14.81
13.76
10.98
9.91
7.56
8.61
3.07
1.12
0.84
0.68
% Of Sales
-
1.72%
2.12%
2.03%
2.47%
3.17%
3.42%
1.77%
0.88%
0.78%
0.84%
Employee Cost
-
67.15
45.58
37.61
29.71
17.92
18.24
12.63
7.69
6.28
4.14
% Of Sales
-
7.78%
7.03%
6.97%
7.40%
7.51%
7.24%
7.30%
6.05%
5.86%
5.13%
Manufacturing Exp.
-
68.23
43.49
37.11
28.56
14.33
16.04
7.42
3.07
1.63
1.54
% Of Sales
-
7.90%
6.70%
6.87%
7.11%
6.00%
6.37%
4.29%
2.42%
1.52%
1.91%
General & Admin Exp.
-
25.50
20.82
12.27
13.78
8.15
7.97
6.54
4.67
3.58
3.00
% Of Sales
-
2.95%
3.21%
2.27%
3.43%
3.41%
3.17%
3.78%
3.68%
3.34%
3.71%
Selling & Distn. Exp.
-
9.95
2.08
5.92
9.41
2.29
2.85
1.46
1.02
0.91
0.67
% Of Sales
-
1.15%
0.32%
1.10%
2.34%
0.96%
1.13%
0.84%
0.80%
0.85%
0.83%
Miscellaneous Exp.
-
3.47
2.33
2.45
0.55
3.10
2.72
3.19
2.66
5.44
0.67
% Of Sales
-
0.40%
0.36%
0.45%
0.14%
1.30%
1.08%
1.84%
2.09%
5.07%
0.82%
EBITDA
328.65
260.93
231.85
195.32
124.81
64.21
59.71
36.19
22.35
11.16
9.20
EBITDA Margin
30.97%
30.23%
35.74%
36.18%
31.07%
26.90%
23.72%
20.91%
17.59%
10.41%
11.39%
Other Income
23.53
41.33
19.03
12.67
9.96
3.66
3.03
3.72
2.10
2.51
2.55
Interest
1.59
1.18
0.58
0.61
0.52
0.34
0.97
0.68
0.77
1.26
1.20
Depreciation
36.97
31.62
23.43
19.00
13.30
7.48
8.38
3.54
1.54
1.24
2.32
PBT
313.62
269.46
226.88
188.38
120.95
60.05
53.39
35.69
22.14
11.17
8.22
Tax
62.18
54.38
50.32
43.74
25.44
14.28
12.26
9.76
8.12
3.14
1.91
Tax Rate
19.83%
20.18%
22.18%
23.22%
21.03%
23.78%
22.96%
27.35%
36.68%
28.11%
23.24%
PAT
251.44
215.00
176.56
144.78
95.61
45.77
41.04
25.85
13.98
8.01
6.28
PAT before Minority Interest
242.25
215.08
176.56
144.63
95.50
45.77
41.13
25.93
14.02
8.03
6.31
Minority Interest
-9.19
-0.08
0.00
0.15
0.11
0.00
-0.09
-0.08
-0.04
-0.02
-0.03
PAT Margin
23.69%
24.91%
27.22%
26.82%
23.80%
19.17%
16.30%
14.93%
11.01%
7.47%
7.77%
PAT Growth
16.91%
21.77%
21.95%
51.43%
108.89%
11.53%
58.76%
84.91%
74.53%
27.55%
 
EPS
33.26
28.44
23.35
19.15
12.65
6.05
5.43
3.42
1.85
1.06
0.83

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Jun 12
Jun 11
Shareholder's Funds
947.91
632.91
363.83
224.76
128.14
93.19
61.74
43.14
33.58
29.08
Share Capital
89.71
51.05
15.12
15.12
15.11
15.11
15.11
15.11
15.11
15.11
Total Reserves
848.76
575.01
345.42
209.56
111.40
78.08
46.63
28.03
18.47
13.97
Non-Current Liabilities
24.86
23.42
27.86
19.90
13.69
10.39
10.42
8.66
4.29
1.82
Secured Loans
0.02
0.29
0.32
0.48
0.73
0.88
2.07
3.48
1.55
0.08
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
5.23
0.13
0.00
0.40
1.63
0.82
0.81
0.38
0.27
0.20
Current Liabilities
144.32
86.11
108.67
113.36
125.04
124.97
107.58
83.01
69.20
40.44
Trade Payables
64.14
60.47
94.23
78.60
55.71
41.56
31.50
25.64
21.26
17.06
Other Current Liabilities
79.28
24.20
13.86
33.09
60.39
72.11
66.42
50.85
38.33
10.71
Short Term Borrowings
0.00
0.00
0.00
0.00
0.00
0.05
0.05
0.05
5.20
9.46
Short Term Provisions
0.91
1.44
0.58
1.67
8.94
11.25
9.60
6.47
4.41
3.22
Total Liabilities
1,125.75
742.52
500.45
358.38
267.14
228.82
179.92
134.90
107.12
71.37
Net Block
272.50
226.84
169.48
151.83
144.23
113.13
102.24
32.71
27.54
24.95
Gross Block
354.79
271.51
231.79
195.15
180.76
142.71
123.06
50.06
43.36
39.53
Accumulated Depreciation
82.29
44.67
62.31
43.31
36.53
29.58
20.82
17.36
15.82
14.58
Non Current Assets
303.23
248.83
196.34
179.16
148.61
146.95
131.30
96.21
53.41
30.12
Capital Work in Progress
20.12
9.70
15.29
3.42
0.23
30.63
24.54
48.98
12.79
0.17
Non Current Investment
0.56
0.33
0.33
13.24
0.44
0.45
0.44
1.19
1.14
1.15
Long Term Loans & Adv.
10.05
11.95
11.23
10.67
3.71
2.75
3.67
10.83
11.94
3.85
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
822.53
493.69
304.11
179.22
118.53
81.87
48.61
38.70
53.71
41.25
Current Investments
60.23
69.62
46.34
4.20
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
238.23
37.45
28.46
22.29
18.81
13.66
9.79
10.42
6.38
5.50
Sundry Debtors
228.96
159.81
125.88
33.02
7.95
5.66
0.09
0.86
7.28
8.33
Cash & Bank
223.43
152.99
79.28
93.07
68.10
45.37
26.82
16.84
31.80
21.62
Other Current Assets
71.68
9.22
6.88
7.32
23.67
17.18
11.90
10.57
8.25
5.80
Short Term Loans & Adv.
56.81
64.61
17.28
19.31
12.58
11.08
8.16
5.61
4.50
3.44
Net Current Assets
678.21
407.58
195.44
65.86
-6.51
-43.10
-58.97
-44.31
-15.49
0.81
Total Assets
1,125.76
742.52
500.45
358.38
267.14
228.82
179.91
134.91
107.12
71.37

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Jun 12
Jun 11
Cash From Operating Activity
44.68
83.42
66.49
67.61
42.40
49.88
59.83
31.95
27.92
14.25
PBT
269.46
226.88
188.38
120.95
60.05
53.39
35.69
22.14
11.17
8.22
Adjustment
7.09
19.12
14.84
8.61
3.87
6.21
2.14
-0.21
-0.25
2.06
Changes in Working Capital
-177.11
-120.06
-100.38
-38.39
-5.13
1.96
29.32
15.81
18.89
4.49
Cash after chg. in Working capital
99.44
125.94
102.84
91.16
58.78
61.56
67.15
37.75
29.81
14.77
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-54.76
-42.51
-36.35
-23.55
-16.38
-11.67
-7.32
-5.80
-1.89
-0.52
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-54.50
-100.46
-69.02
-36.11
-5.72
-22.66
-43.89
-45.44
-16.44
-6.90
Net Fixed Assets
-43.65
58.45
-48.43
-19.56
-7.66
-25.72
-48.50
-43.00
-16.08
Net Investments
-27.53
-120.03
-29.43
-17.35
0.01
-0.90
0.75
-0.05
-0.04
Others
16.68
-38.88
8.84
0.80
1.93
3.96
3.86
-2.39
-0.32
Cash from Financing Activity
79.77
89.79
-11.60
-6.74
-13.95
-8.67
-5.96
-1.48
-1.30
-0.37
Net Cash Inflow / Outflow
69.94
72.76
-14.13
24.76
22.73
18.55
9.99
-14.97
10.18
6.98
Opening Cash & Equivalents
150.65
77.17
91.31
66.55
45.37
26.82
16.84
31.80
21.62
14.64
Closing Cash & Equivalent
220.77
150.65
77.17
91.31
68.10
45.37
26.82
16.84
31.80
21.62

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Jun 12
Jun 11
Book Value (Rs.)
114.21
78.03
47.69
29.73
16.25
11.84
7.68
5.22
3.95
3.36
ROA
23.02%
28.41%
33.68%
30.54%
18.46%
20.12%
16.48%
11.59%
9.00%
8.84%
ROE
29.58%
37.14%
49.43%
54.97%
43.13%
55.78%
53.24%
40.49%
29.10%
24.90%
ROCE
33.46%
45.59%
64.08%
69.03%
55.41%
71.11%
68.99%
56.69%
34.62%
26.87%
Fixed Asset Turnover
2.76
2.58
2.53
2.14
1.48
1.89
2.00
2.73
2.61
2.04
Receivable days
82.19
80.37
53.72
18.62
10.40
4.17
1.00
11.66
26.30
37.63
Inventory Days
58.28
18.54
17.16
18.68
24.83
17.00
21.31
24.06
20.01
24.84
Payable days
28.33
65.76
89.68
88.17
103.48
69.75
79.69
85.60
79.07
88.42
Cash Conversion Cycle
112.15
33.15
-18.80
-50.88
-68.24
-48.58
-57.39
-49.89
-32.75
-25.95
Total Debt/Equity
0.04
0.00
0.00
0.00
0.02
0.02
0.06
0.12
0.23
0.38
Interest Cover
228.51
391.22
309.72
235.08
179.35
56.11
53.29
29.73
9.88
7.84

News Update:


  • Caplin Point Laboratories’ arm gets USFDA approval for Sumatriptan Injection
    14th Jul 2021, 15:07 PM

    Sumatriptan Injection USP is indicated in adults for acute treatment of migraine with or without aura, and acute treatment of cluster headache

    Read More
  • Caplin Point Laboratories’ arm gets USFDA nod for Prochlorperazine Edisylate Injection
    23rd Apr 2021, 13:27 PM

    Prochlorperazine Edisylate Injection is an antiemetic and is indicated for the control of severe nausea and vomiting

    Read More
  • Caplin Point Laboratories’ arm gets USFDA’s nod for Neostigmine Methylsulfate Injection
    22nd Apr 2021, 11:05 AM

    Neostigmine Methylsulfate Injection had US sales data of approximately $20 million for the 12-month period ending December 2020

    Read More
  • Caplin Point Laboratories’ arm gets USFDA nod for Milrinone Lactate Injection
    19th Apr 2021, 13:46 PM

    Milrinone lactate injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.